138199 |
United States |
Collaborative Testing Services
Collaborative Testing Services
|
CTS Agriculture Laboratory Proficiency (ALP) Program: Water
CTS Agriculture Laboratory Proficiency (ALP) Program: Water
|
2024-07-18 |
|
Tested property |
(Sum Cations, SAR, ADJ-SAR) |
|
134427 |
United Kingdom |
LGC AXIO Proficiency Testing
LGC AXIO Proficiency Testing
|
Water Microbiology Scheme - (QWAS)
Water Microbiology Scheme - (QWAS)
|
2021-03-01 |
|
Tested property |
(SARS-CoV-2) (Detection of SARS-CoV-2) (Optional quantification of SARS-CoV-2 (Trial)) |
Testing method |
(2 x 1.5 ml vial (A & B) of non-infectious, SARS-CoV-2 virus (whole genome) 1 x >100ml sterile water diluent 1 x >20g sterile sludge matrix) |
|
302644 |
United Kingdom |
LGC AXIO Proficiency Testing
LGC AXIO Proficiency Testing
|
Environmental Hygiene Monitoring Scheme- HYGIENE
Environmental Hygiene Monitoring Scheme- HYGIENE
|
2021-09-06 |
|
Test item |
(Surface testing (swab rinsate) for SARS-CoV-2 molecular) |
Tested property |
(SARS-CoV-2) |
|
820055 |
United Kingdom |
INSPEC International Limited
INSPEC International Limited
|
Personal Protective Equipment
[Personal Protective Equipment]
Personal Protective Equipment
[Personal Protective Equipment]
|
2024-10-20 |
|
Related legislation or standard |
(European PPE Regulation (EU 2016/425)
National legislation regarding PPE for Covid-19) |
|
699949 |
United Kingdom |
UK NEQAS for Immunology, Immunochemistry & Allergy
UK NEQAS for Immunology, Immunochemistry & Allergy
|
UK NEQAS for SARS-CoV-2 / COVID-19 Antibodies
UK NEQAS for SARS-CoV-2 / COVID-19 Antibodies
|
2023-05-30 |
|
PT name |
(UK NEQAS for SARS-CoV-2 / COVID-19 Antibodies) |
Tested property |
(SARS-CoV-2 / COVID-19 Antibodies) |
|
769005 |
United Kingdom |
LGC AXIO Proficiency Testing
LGC AXIO Proficiency Testing
|
SARS-CoV-2 Proficiency Testing Scheme
SARS-CoV-2 Proficiency Testing Scheme
|
2022-05-04 |
|
PT name |
(SARS-CoV-2 Proficiency Testing Scheme) |
Test item |
(SARS-CoV-2 (Serological)- 3 x 0.75 ml samples for detection for the SARS-CoV-2 antibodies -NEW 2020) (SARS-CoV-2 (Molecular)- 2 x 1.5ml samples for SARS-CoV-2 virus -NEW 2020) (SARS-CoV-2 antigen - 3 x swab based samples (A, B, and C). Non-infectious simulated patient) (nasopharyngeal samples containing the SARS-CoV-2 nucleocapsid protein.) (SARS-CoV-2 (Molecular)- 2 x swab based samples. Non-infectious simulated nasopharyngeal samples) |
Tested property |
(SARS-CoV-2 IgA, IgG, IgM, Total antibodies) (SARS-CoV-2 virus) (SARS-CoV-2 virus) (SARS-CoV-2 virus - The samples contain the whole genome) (SARS-CoV-2 virus - The samples contain the whole genome) |
Testing method |
(The samples are derived from naturally occurring material collected via apheresis from patients that have recovered from COVID-19.) |
|
925094 |
United Kingdom |
UK NEQAS for Microbiology
UK NEQAS for Microbiology
|
Molecular detection of SARS-CoV-2
[Molecular detection of SARS-CoV-2]
Molecular detection of SARS-CoV-2
[Molecular detection of SARS-CoV-2]
|
2022-05-13 |
|
PT name |
(Molecular detection of SARS-CoV-2) |
Scheme name in national language |
(Molecular detection of SARS-CoV-2) |
Test item |
(/ absence of SARS-CoV-2 nucleic acid by molecular methods, genotyping of SARS-CoV-2 (if performed)) |
Tested property |
(SARS-CoV-2 nucleic acid) |
|
1144039 |
United Kingdom |
Weqas
Weqas
|
POCT Respiratory Virus
[POCT Respiratory Virus]
POCT Respiratory Virus
[POCT Respiratory Virus]
|
2024-10-01 |
|
Remarks |
(targeted for Influenza A (and subtypes) Influenza B, SARS-Cov-2, and Respiratory Syncytial Virus) (), influenza B, RSV, SARS-Cov-2 or no virus. A range of differing viral loads are distributed including) (reporting for SARS-CoV-2 Ag (RNA), Influenza A, Influenza B and RSV available.
For more information) |
Tested property |
(SARS-CoV-2 Ag (RNA)) |
|
1217643 |
United Kingdom |
UK NEQAS for Microbiology
UK NEQAS for Microbiology
|
Respiratory viruses Point of Care
[Respiratory viruses Point of Care]
Respiratory viruses Point of Care
[Respiratory viruses Point of Care]
|
2024-09-24 |
|
Tested property |
(Detection of antigens /nucleic acid for SARS-CoV-2, influenza and RSV using POCT devices) |
|
143957 |
United Kingdom |
Public Health England
Public Health England
|
Food and Environmental Proficiency Testing Unit (FEPTU)
Food and Environmental Proficiency Testing Unit (FEPTU)
|
2025-04-15 |
|
Tested property |
(SARS-CoV-2) |
|
883284 |
Thailand |
Department of Medical Sciences PT provider (DMSc PT provider)
Department of Medical Sciences PT provider (DMSc PT provider)
|
SARS-CoV-2 detection by Real-time RT-PCR
[SARS-CoV-2 ด้วยวิธี Real-time RT-PCR (สถาบันวิจัยวิทยาศาสตร์สาธารณสุข)]
SARS-CoV-2 detection by Real-time RT-PCR
[SARS-CoV-2 ด้วยวิธี Real-time RT-PCR (สถาบันวิจัยวิทยาศาสตร์สาธารณสุข)]
|
2024-01-09 |
|
PT name |
(SARS-CoV-2 detection by Real-time RT-PCR) |
Scheme name in national language |
(SARS-CoV-2 ด้วยวิธี Real-time RT-PCR (สถาบันวิจัยวิทยาศาสตร์สาธารณสุข)) |
|
1129430 |
Spain |
ielab
ielab
|
SARS-CoV-2
[SARS-CoV-2]
SARS-CoV-2
[SARS-CoV-2]
|
2023-11-29 |
|
PT name |
(SARS-CoV-2) |
Scheme name in national language |
(SARS-CoV-2) |
Tested property |
(SARS-CoV-2) |
|
706310 |
Portugal |
Programa Nacional de Avaliação Externa da Qualidade (PNAEQ) INSA DEP UAEQ
Programa Nacional de Avaliação Externa da Qualidade (PNAEQ) INSA DEP UAEQ
|
SARS-CoV-2, molecular detection
[SARS-CoV-2, molecular detection]
SARS-CoV-2, molecular detection
[SARS-CoV-2, molecular detection]
|
2024-03-13 |
|
PT name |
(SARS-CoV-2, molecular detection) |
Scheme name in national language |
(SARS-CoV-2, molecular detection) |
Tested property |
(SARS-CoV-2 virus) |
|
1271562 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
Virus serology: SARS-CoV-2
[Vírus szerológia: SARS-CoV-2]
Virus serology: SARS-CoV-2
[Vírus szerológia: SARS-CoV-2]
|
2024-10-08 |
|
PT name |
(Virus serology: SARS-CoV-2) |
Remarks |
(The content of the scheme: SARS-CoV-2 antibody (IgG-, IgG-S, IgG-N, IgM, IgA, total antibody) |
Scheme name in national language |
(Vírus szerológia: SARS-CoV-2) |
Tested property |
(Anti-SARS-CoV-2 total (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG-S (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG-N (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgM (OD, S/CO, quantitative, evaluation)) |
|
1271523 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
POCT: SARS-CoV-2
[POCT: SARS-CoV-2]
POCT: SARS-CoV-2
[POCT: SARS-CoV-2]
|
2024-10-08 |
|
PT name |
(POCT: SARS-CoV-2) |
Remarks |
(The content of the scheme: SARS-CoV-2 antibody (IgG, IgM, total antibody) and antigen determination) |
Scheme name in national language |
(POCT: SARS-CoV-2) |
Tested property |
(Anti-SARS-CoV-2 total qualitative) (Anti-SARS-CoV-2 - IgG qualitative) (Anti-SARS-CoV-2 - IgM qualitative) (SARS-CoV-2 Antigen qualitative) (SARS-CoV-2 interpretation) |
|
1271426 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
Virus nucleic acid determination: SARS-CoV-2
[Vírus nukleinsav meghatározás: SARS-CoV-2]
Virus nucleic acid determination: SARS-CoV-2
[Vírus nukleinsav meghatározás: SARS-CoV-2]
|
2024-11-25 |
|
PT name |
(Virus nucleic acid determination: SARS-CoV-2) |
Remarks |
(amplification techniques (NAT) for qualitative determination of SARS-CoV-2 virus.
Qualitative results are) |
Scheme name in national language |
(Vírus nukleinsav meghatározás: SARS-CoV-2) |
|
1163321 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – Respiratory Virus Panel 2 for Multiplex Tests (432)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 2 für Multiplex Teste (432)]
Virus Genome Detection – Respiratory Virus Panel 2 for Multiplex Tests (432)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 2 für Multiplex Teste (432)]
|
2024-04-16 |
|
Tested property |
(influenza A and B viruses incl. avian influenza A viruses, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated)) |
|
1163304 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – Respiratory Virus Panel 1 for Multiplex Tests (431)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 1 für Multiplex Teste (431)]
Virus Genome Detection – Respiratory Virus Panel 1 for Multiplex Tests (431)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 1 für Multiplex Teste (431)]
|
2024-04-16 |
|
Tested property |
(incl. avian influenza A viruses, parecho, parainfluenza, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated), respectively) |
|
1163345 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – SARS-CoV-2 sequence analysis (417)
[Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)]
Virus Genome Detection – SARS-CoV-2 sequence analysis (417)
[Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)]
|
2024-04-16 |
|
PT name |
(Virus Genome Detection – SARS-CoV-2 sequence analysis (417)) |
Remarks |
(Please note:
Starting in 2024, only results of SARS-CoV-2 sequence analyses for SARS-CoV-2) |
Scheme name in national language |
(Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)) |
Tested property |
(Differentiation of SARS-CoV-2 variants with clinical relevance using whole genome sequencing) |
|
1163338 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – SARS-CoV-2 (409)
[Virusgenom-Nachweis - SARS-CoV-2 (409)]
Virus Genome Detection – SARS-CoV-2 (409)
[Virusgenom-Nachweis - SARS-CoV-2 (409)]
|
2024-04-16 |
|
PT name |
(Virus Genome Detection – SARS-CoV-2 (409)) |
Scheme name in national language |
(Virusgenom-Nachweis - SARS-CoV-2 (409)) |
Tested property |
(The sample set contains defined samples with SARS-CoV-2 (full virus, inactivated) and, if necessary) (Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV-2) |
|